Castle Biosciences, Inc.

Healthcare · Diagnostics & Research · United States

Last price 38.51 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.18B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasi...